DOCSLIB.ORG

Liothyronine Sodium(BANM, Rinnm) Potassium Perchlorate

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Liothyronine Sodium(BANM, Rinnm) Potassium Perchlorate 2174 Thyroid and Antithyroid Drugs with methodological limitations. However, a controlled trial of In myxoedema coma liothyronine sodium may be liothyronine with paroxetine could not confirm any advantage of given intravenously in a dose of 5 to 20 micrograms by 3 O additive therapy. slow intravenous injection, repeated as necessary, usu- 1. Aronson R, et al. Triiodothyronine augmentation in the treat- HO I ally at intervals of 12 hours; the minimum interval be- ment of refractory depression: a meta-analysis. Arch Gen Psychi- OH atry 1996; 53: 842–8. tween doses is 4 hours. An alternative regimen advo- 2. Altshuler LL, et al. Does thyroid supplementation accelerate tri- NH2 cates an initial dose of 50 micrograms intravenously cyclic antidepressant response? A review and meta-analysis of I O the literature. Am J Psychiatry 2001; 158: 1617–22. followed by further injections of 25 micrograms every 3. Appelhof BC, et al. Triiodothyronine addition to paroxetine in I 8 hours until improvement occurs; the dosage may the treatment of major depressive disorder. J Clin Endocrinol then be reduced to 25 micrograms intravenously twice Metab 2004; 89: 6271–6. (liothyronine) daily. Obesity. Thyroid drugs have been tried in the treatment of obes- Liothyronine has also been given in the diagnosis of ity (p.2149) in euthyroid patients, but they produce only tempo- NOTE. The abbreviation T3 is often used for endogenous tri-io- hyperthyroidism in adults. Failure to suppress the up- rary weight loss, mainly of lean body-mass, and can produce se- dothyronine in medical and biochemical reports. Liotrix is USAN rious adverse effects, especially cardiac complications.1 for a mixture of liothyronine sodium with levothyroxine sodium. take of radio-iodine after several days of receiving lio- Hypothyroidism has also been reported2 when these drugs were Pharmacopoeias. In Eur. (see p.vii), Jpn, and US. thyronine sodium suggests a diagnosis of hyperthy- withdrawn from previously euthyroid patients being treated for Ph. Eur. 6.2 (Liothyronine Sodium). A white or almost white or roidism. simple obesity. Levothyroxine appears to have been abused by slightly coloured powder. Practically insoluble in water; slightly Liothyronine hydrochloride has also been used. some athletes to promote weight loss.3 soluble in alcohol. It dissolves in dilute solutions of alkali hy- 1. Rivlin RS. Therapy of obesity with hormones. N Engl J Med droxides. Store at 2° to 8° in airtight containers. Protect from Preparations 1975; 292: 26–9. light. BP 2008: Liothyronine Tablets; 2. Dornhorst A, et al. Possible iatrogenic hypothyroidism. Lancet USP 31 (Liothyronine Sodium). A light tan, odourless, crystal- USP 31: Liothyronine Sodium Tablets; Liotrix Tablets. 1981; i: 52. line powder. Very slightly soluble in water; slightly soluble in al- Proprietary Preparations (details are given in Part 3) 3. MacAuley D. Drugs in sport. BMJ 1996; 313: 211–15. cohol; practically insoluble in most other organic solvents. Store Austral.: Te r t r ox i n ; Braz.: Cynomel†; Canad.: Cytomel; Cz.: Tertroxin†; in airtight containers. Fr.: Cynomel; Ger.: Thybon; Thyrotardin N; Gr.: Cynomel†; T-3; Ital.: Dis- Urticaria. There is some suggestion that chronic urticaria pon†; Ti-Tre; Mex.: Cynomel; Liotrex; Triyotex; Neth.: Cytomel; NZ: Ter- (p.1584) may be associated with thyroid autoimmunity and that troxin; Port.: Neo-Tiroimade; S.Afr.: Ter troxin; Thai.: Tertroxin†; Turk.: treatment with thyroid hormones may result in clinical remis- Adverse Effects, Treatment, and Precau- Tiromel; UK: Tertroxin†; Triiodothyronine Injection; USA: Cytomel; Trio- sion.1 In one study, a nine-year-old boy was successfully treated tions stat; Venez.: Te r t r ox i n† . for chronic urticaria with levothyroxine therapy at doses of 50 to As for Levothyroxine Sodium, p.2171. Multi-ingredient: Arg.: Eutroid; Levotrin; Tresite F; Austria: Combithy- 2 rex; Novothyral; Prothyrid; Belg.: Novothyral; Braz.: Tyroplus†; Chile: 100 micrograms daily. The authors advised screening for thy- Novothyral; Cz.: Novothyral†; Thyreotom; Fr.: Euthyral; Ger.: NeyNormin roid function and anti-thyroid microsomal antibodies in cases of Interactions N (Revitorgan-Dilutionen N Nr 65)†; NeyTumorin N (Revitorgan-Dilutio- chronic urticaria as these patients may benefit from thyroid hor- nen N Nr 66)†; Novothyral; Prothyrid; Thyreotom†; Gr.: Dithyron; Ital.: mone therapy. A small investigative study concluded that treat- As for Levothyroxine Sodium, p.2172. Tiroide Amsa; Mex.: Cynoplus; Novotiral; Proloid S†; Redotex; Pol.: Novothyral; Rus.: Novothyral (Новотирал); Thyreocomb (Тиреокомб); ment with levothyroxine sodium (in hypothyroid patients) or Thyreotom (Тиреотом); S.Afr.: Diotroxin; Switz.: Novothyral; Turk.: Biti- antithyroid drugs (in patients with Graves’ disease) is of benefit Pharmacokinetics ron; USA: Thyrolar. in patients with severe chronic urticaria associated with thyroid Liothyronine is readily and almost completely ab- autoimmunity.3 sorbed from the gastrointestinal tract. Once in the cir- 1. Rumbyrt JS, et al. Resolution of chronic urticaria in patients with culation, liothyronine binds principally to thyroxine- thyroid autoimmunity. J Allergy Clin Immunol 1995; 96: 901–5. binding globulin (TBG), although less strongly than Potassium Perchlorate 2. Dreyfus DH, et al. Steroid-resistant chronic urticaria associated with anti-thyroid microsomal antibodies in a nine-year-old boy. levothyroxine; some is also bound to thyroxine-bind- Chloristan draselný; Kalii perchloras; Kalio perchloratas; Ka- J Pediatr 1996; 128: 576–8. ing pre-albumin (TBPA) or to albumin. Liothyronine liumperkloraatti; Kaliumperklorat; Kálium-perklorát; Perclorato 3. Gaig P, et al. Successful treatment of chronic idiopathic urticaria has a plasma half-life in euthyroidism of about 1 to 2 potásico; Potassium, perchlorate de. associated with thyroid autoimmunity J Investig Allergol Clin KClO = 138.5. days; the half-life is prolonged in hypothyroidism and 4 Immunol 2000; 10: 342–5. CAS — 7778-74-7. reduced in hyperthyroidism. Preparations ATC — H03BC01. Liothyronine is metabolised by deiodination to inac- ATC Vet — QH03BC01. BP 2008: Levothyroxine Tablets; USP 31: Levothyroxine Sodium Tablets; Liotrix Tablets. tive di-iodothyronine and mono-iodothyronine. Iodine released by deiodination is largely reused within the Proprietary Preparations (details are given in Part 3) thyroid cells. Further metabolites result from deamina- K+ Arg.: Euthyrox; Juno†; T4; Austral.: Eutroxsig; Oroxine; Austria: Euthyrox; O- Neothyron; Thyrex; Belg.: Elthyrone; Euthyrox; Thyrax; Braz.: Euthyrox; tion and decarboxylation to tiratricol (triac). Puran T4; Synthroid; Tetroid; Tiroidin; Canad.: Eltroxin; Euthyrox; Syn- O Cl O throid; Chile: Esaldox; Eutirox; Cz.: Eltroxin; Euthyrox; Letrox; Thyrax†; Uses and Administration Denm.: Eltroxin; Fr.: Levothyrox; Ger.: Berlthyrox; Eferox; Euthyrox; L- O Thyrox; Lixin; Thevier; Gr.: Levothroid; T-4; Thyro-4; Thyrohormone; Liothyronine is a thyroid hormone (see p.2165). It is Hong Kong: Eltroxin; Hung.: Euthyrox; Letrox; India: Eltroxin; Indon.: Euthyrox; Thyrax; Irl.: Eltroxin; Israel: Eltroxin; Ital.: Eutirox; Tiracrin; Ti- used in the treatment of hypothyroidism (p.2167), and Pharmacopoeias. In Eur. (see p.vii) and US. rosint; Jpn: Thyradin-S; Malaysia: Oroxine; Mex.: Abutiroi; Cynocuatro; is believed to be more active than levothyroxine Ph. Eur. 6.2 (Potassium Perchlorate). A white or almost white Daltroid†; Eutirox; Sintrocid†; Tiroidine; Neth.: Eltroxin; Euthyrox; Thyrax; Norw.: Levaxin; NZ: Eltroxin; Philipp.: Eltroxin; Euthyrox; Thyrax; Thyro- (p.2173). The onset of action of liothyronine is rapid, crystalline powder or colourless crystals. Sparingly soluble in hex; Pol.: Eferox; Eltroxin; Euthyrox; Letrox; Port.: Eutirox; Letequatro; developing within a few hours, and therefore it tends to water; practically insoluble in alcohol. Letter; Thyrax; Rus.: Bagothyrox (Баготирокс); Euthyrox (Эутирокс); be used in circumstances where this, and its short dura- USP 31 (Potassium Perchlorate). pH of a 0.1M solution in water S.Afr.: Eltroxin; Singapore: Eltroxin; Euthyrox; Oroxine; Spain: Dexnon; is between 5.0 and 6.5. Eutirox; Levothroid; Swed.: Euthyrox; Levaxin; Switz.: Eltroxine; Euthyrox; tion of action, are useful, particularly in hypothyroid Thai.: Elthyro; Eltroxin; Euthyrox; Pondtroxin; Thyrosit; Turk.: Levotiron; Te fo r ; UK: Eltroxin; Evotrox; USA: Levothroid; Levoxyl; Novothyrox; Syn- (myxoedema) coma. Sodium Perchlorate throid; Unithroid; Venez.: Euthyrox; Thyrax. With regular dosing the peak therapeutic effect is usu- Perclorato sódico; Sodu nadchloran. Multi-ingredient: Arg.: Eutroid; Levotrin; Austria: Combithyrex; Jodthy- ally achieved after 3 days; on withdrawal its effects rox; Novothyral; Prothyrid; Belg.: Novothyral; Braz.: Tyroplus†; Chile: NaClO4 = 122.4. Novothyral; Cz.: Jodthyrox; Novothyral†; Thyreotom; Fr.: Euthyral; Ger.: may persist for 1 to 3 days. CAS — 7601-89-0 (anhydrous sodium perchlorate); 7791- Eferox Jod; Jodthyrox; L-Thyrox Jod; Novothyral; Prothyrid; Thyreocomb 07-3 (sodium perchlorate monohydrate). N†; Thyreotom†; Thyronajod; Gr.: Dithyron; Ital.: Dermocinetic; Somato- The dose of liothyronine should be individualised on line; Tiroide Amsa; Mex.: Cynoplus; Novotiral; Proloid S†; Pol.: Jodthyrox; the basis of clinical response and biochemical tests and Novothyral; Rus.: Jodthyrox (Йодтирокс); Novothyral (Новотирал); Thy- should be monitored regularly. Although liothyronine Na+ reocomb (Тиреокомб); Thyreotom (Тиреотом);
Load more

Recommended publications
  • Thyroid Hormone Misuse and Abuse
    Endocrine (2019) 66:79–86 https://doi.org/10.1007/s12020-019-02045-1 REVIEW Thyroid hormone misuse and abuse Victor J. Bernet 1,2 Received: 11 June 2019 / Accepted: 2 August 2019 © Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Thyroid hormone (TH) plays an essential role in human physiology and maintenance of appropriate levels is important for good health. Unfortunately, there are instances in which TH is misused or abused. Such misuse may be intentional such as when individuals take thyroid hormone for unapproved indications like stimulation of weight loss or improved energy. There are instances where healthcare providers prescribe thyroid hormone for controversial or out of date uses and sometimes in supraphysiologic doses. Othertimes, unintentional exposure may occur through supplements or food that unknowingly contain TH. No matter the reason, exposure to exogenous forms of TH places the public at risk for potential adverse side effects. Keywords Thyrotoxicosis ● Thyroid hormone abuse ● Thyroid hormone misuse ● Factitious thyrotoxicosis ● Supplements ● 1234567890();,: 1234567890();,: Analogs Overdose Thyroid hormone misuse and abuse secondary to exogenous TH ingestion that may be unin- tentional or purposeful such as in some cases of Munch- Almost any substance that impacts body physiology and ausen syndrome. Instances of TH misuse can be associated function is at risk for misuse or frank abuse, usually in the with the development of significant side effects. There are misgiven belief that the particular agent whether it be a other instances of chronic, low-grade over treatment with herb, supplement, medication, or hormone has healing TH, which occur for various misreasoning such as weight properties beyond that of which it actually possesses.
    [Show full text]
  • Salutary Lessons from TGA-Approved Sources for Thyroid-Related Medications
    REVIEW Barriers in the quest for quality drug information: salutary lessons from TGA-approved sources for thyroid-related medications Jim R Stockigt n iodine-replete countries, about 5% of the population have a ABSTRACT thyroid disorder,1 of whom about a quarter will require long- • term medication either to correct deficiency or to control Product information (PI) for thyroid-related medications I endorsed by the Therapeutic Goods Administration, as thyroid hormone excess. In 2005, about 700 000 Pharmaceutical Benefits Scheme prescriptions were filled in Australia for thyrox- reproduced in the commonly used compilation publications ine, with about 80 000 scripts for the antithyroid drugs carbima- June 2006 MIMS (Monthly index of medical specialties) zole and propylthiouracil.2 annual, MIMS Online and the Australian prescription products Although no major new therapeutic agent has been introduced in guide 2006, was evaluated to see whether it reflects The Medical Journal of Australia ISSN: 0025- contemporary therapeutic practice. the thyroid729X 15 field January for 2007some 186 years, 2 76-79 the body of knowledge and • evidence©The has Medicaladvanced. Journal It is important of Australia that these 2007 developments are Compared with current medical literature, these PI-based reflectedwww.mja.com.au in the product information (PI) widely used by medical sources provide inadequate, inaccurate or outdated practitionersReview and a range of health professionals, who may not refer therapeutic directives. Examples include: directly to current scientific literature on thyroid disorders. MIMS ¾ Incorrect advice that thyroxine therapy should always 3 (Monthly index of medical specialties) annual, in its 30th edition in begin at very low dosage.
    [Show full text]
  • Package Insert TECHNETIUM Tc99m GENERATOR for the Production of Sodium Pertechnetate Tc99m Injection Diagnostic Radiopharmaceuti
    NDA 17693/S-025 Page 3 Package Insert TECHNETIUM Tc99m GENERATOR For the Production of Sodium Pertechnetate Tc99m Injection Diagnostic Radiopharmaceutical For intravenous use only Rx ONLY DESCRIPTION The technetium Tc99m generator is prepared with fission-produced molybdenum Mo99 adsorbed on alumina in a lead-shielded column and provides a means for obtaining sterile pyrogen-free solutions of sodium pertechnetate Tc99m injection in sodium chloride. The eluate should be crystal clear. With a pH of 4.5-7.5, hydrochloric acid and/or sodium hydroxide may have been used for Mo99 solution pH adjustment. Over the life of the generator, each elution will provide a yield of > 80% of the theoretical amount of technetium Tc99m available from the molybdenum Mo99 on the generator column. Each eluate of the generator should not contain more than 0.0056 MBq (0.15 µCi) of molybdenum Mo99 per 37 MBq, (1 mCi) of technetium Tc99m per administered dose at the time of administration, and not more than 10 µg of aluminum per mL of the generator eluate, both of which must be determined by the user before administration. Since the eluate does not contain an antimicrobial agent, it should not be used after twelve hours from the time of generator elution. PHYSICAL CHARACTERISTICS Technetium Tc99m decays by an isomeric transition with a physical half-life of 6.02 hours. The principal photon that is useful for detection and imaging studies is listed in Table 1. Table 1. Principal Radiation Emission Data1 Radiation Mean %/Disintegration Mean Energy (keV) Gamma-2 89.07 140.5 1Kocher, David C., “Radioactive Decay Data Tables,” DOE/TIC-11026, p.
    [Show full text]
  • EANM Practice Guideline/SNMMI Procedure Standard for RAIU and Thyroid Scintigraphy
    European Journal of Nuclear Medicine and Molecular Imaging (2019) 46:2514–2525 https://doi.org/10.1007/s00259-019-04472-8 GUIDELINES EANM practice guideline/SNMMI procedure standard for RAIU and thyroid scintigraphy Luca Giovanella 1,2 & Anca M. Avram3 & Ioannis Iakovou4 & Jennifer Kwak5 & Susan A. Lawson3 & Elizabeth Lulaj6 & Markus Luster7 & Arnoldo Piccardo8 & Matthias Schmidt9 & Mark Tulchinsky10 & Frederick A. Verburg7 & Ely Wolin11 Received: 11 July 2019 /Accepted: 29 July 2019 / Published online: 7 August 2019 # Springer-Verlag GmbH Germany, part of Springer Nature 2019 Abstract Introduction Scintigraphic evaluation of the thyroid gland enables determination of the iodine-123 iodide or the 99mTc-pertechnetate uptake and distribution and remains the most accurate method for the diagnosis and quantification of thyroid autonomy and the detection of ectopic thyroid tissue. In addition, thyroid scintigraphy and radioiodine uptake test are useful to discriminate hyperthyroidism from destructive thyrotoxicosis and iodine-induced hyperthyroidism, respectively. Methods Several radiopharmaceuticals are available to help in differentiating benign from malignant cytologically indeterminate thyroid nodules and for supporting clinical decision-making. This joint practice guideline/procedure standard from the European Association of Nuclear Medicine (EANM) and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) provides recommendations based on the available evidence in the literature. Conclusion The purpose of this practice guideline/procedure standard is to assist imaging specialists and clinicians in recommending, performing, and interpreting the results of thyroid scintigraphy (including positron emission tomography) with various radiopharmaceuticals and radioiodine uptake test in patients with different thyroid diseases. Keywords Thyroid . Scintigraphy . Radioiodine uptake test . 99mTc-sestaMIBI, 18F-fluorodeoxyglucose Preamble approval of the Committee on Guidelines and Board of Directors of both organizations.
    [Show full text]
  • Common Thyroid Disorders
    9/7/17 Common Louie Riesch MSN, MPH, RN, ACNS-BC, CDE Thyroid Texas Diabetes and Endocrinology Disorders Anatomy of the Thyroid Gland Hypothalamic-Pituitary-Thyroid Axis Physiology Hypothalamus TRH • TSH reflects tissue thyroid – hormone actions • TSH as an index of Pituitary therapeutic success and – potential toxicity TSH T4 Target Tissues T3 Heart Thyroid Gland Liver T4 T3 TR Bone T4 è T3 Liver CNS 1 9/7/17 Production of T4 and T3 Ê T4 is the primary secretory product of the thyroid gland, which is the only source of T4 Ê The thyroid secretes approximately 100 nmol of T4 per day Ê T3 is derived from 2 processes Ê The total daily production rate of T3 is about 15-30 µg Ê About 80% of circulating T3 comes from deiodination of T4 in peripheral tissues Ê Largely liver and kidneys Ê About 20% comes from direct thyroid secretion Free Hormone Concept Ê Only unbound (free) hormone has metabolic activity and physiologic effects Ê Total hormone concentration Ê Normally is kept proportional to the concentration of carrier proteins Ê Is kept appropriate to maintain a constant free hormone level 2 9/7/17 Drugs and Conditions That Increase Serum T4 and T3 Levels by Increasing TBG Drugs that increase TBG Conditions that increase TBG Ê Oral contraceptives and other Ê Pregnancy sources of estrogen Ê Infectious/chronic active Ê Methadone hepatitis Ê Clofibrate Ê HIV infection Ê 5-Fluorouracil Ê Biliary cirrhosis Ê Heroin Ê Acute intermittent porphyria Ê Tamoxifen Ê Genetic factors Evaluate for thyroid disease Ê All >35 years of age, every 5 years Ê
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Summary of Product Characteristics
    Health Products Regulatory Authority Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Ultra-TechneKow FM 2.15-43.00 GBq radionuclide generator 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Sodium pertechnetate (99mTc) injection is produced by means of a (99Mo/99mTc) generator. Technetium (99mTc) decays with the emission of gamma radiation with a mean energy of 140 keV and a half-life of 6.01 hours to technetium (99Tc) which, in view of its long half-life of 2.13 x 105 years can be regarded as quasi stable. The radionuclide generator containing the parent isotope 99Mo, adsorbed on a chromatographic column delivers sodium pertechnetate (99mTc) injection in sterile solution. The 99Mo on the column is in equilibrium with the formed daughter isotope 99mTc. The generators are supplied with the following 99Mo activity amounts at activity reference time which deliver the following technetium (99mTc) amounts, assuming a 100% theoretical elution yield and 24 hours time from previous elution and taking into account that branching ratio of 99Mo is about 87%: 99mTc activity (maximum theoretical elutable 1.90 3.81 5.71 7.62 9.53 11.43 15.24 19.05 22.86 26.67 30.48 38.10 GBq activity at ART, 06.00 h CET) 99Mo activity (at ART, 06.00 h 2.15 4.30 6.45 8.60 10.75 12.90 17.20 21.50 25.80 30.10 34.40 43.00 GBq CET) The technetium (99mTc) amounts available by a single elution depend on the real yields of the kind of generator used itself declared by manufacturer and approved by National Competent Authority.
    [Show full text]
  • Thyroid Function Testing and Management During and After Pregnancy Among Women Without Thyroid Disease Before Pregnancy
    RESEARCH HEALTH SERVICES Thyroid function testing and management during and after pregnancy among women without thyroid disease before pregnancy Jennifer M. Yamamoto MD, Amy Metcalfe PhD, Kara A. Nerenberg MD, Rshmi Khurana MD, Alex Chin PhD, Lois E. Donovan MD n Cite as: CMAJ 2020 June 1;192:E596-602. doi: 10.1503/cmaj.191664 ABSTRACT BACKGROUND: Screening in pregnancy between October 2014 and September initiated at a median gestational age of for subclinical hypothyroidism, often 2017. We used delivery records, phys- 7 (interquartile range 5–12) weeks. defined as thyroid-stimulating hormone ician billings, and pharmacy and labora- Among women with first TSH measure- (TSH) greater than 2.5 mIU/L or greater tory administrative data. Our key out- ments of 4.01 to 9.99 mIU/L who were than 4.0 mIU/L, is controversial. We comes were characteristics of TSH not immediately treated, the repeat TSH determined the frequency and distribu- testing and the initiation and continua- measurement was 4.00 mIU/L or below tion of TSH testing by gestational age, tion of thyroid hormone therapy. We in 67.9% of pregnancies. Thyroid hor- as well as TSH values associated with calculated the proportion of pregnan- mone was continued post partum for treatment during pregnancy and the fre- cies with thyroid testing and the fre- 44.6% of the women who started ther- quency of postpartum continuation of quency of each specific thyroid test. apy during their pregnancy. thyroid hormone therapy. RESULTS: Of the 188 490 pregnancies INTERPRETATION: The findings of our METHODS: We performed a retrospec- included, 111 522 (59.2%) had at least study suggest that current practice pat- tive cohort study of pregnancies in 1 TSH measurement.
    [Show full text]
  • Liothyronine Sodium(BANM, Rinnm) Potassium Perchlorate
    2174 Thyroid and Antithyroid Drugs with methodological limitations. However, a controlled trial of In myxoedema coma liothyronine sodium may be liothyronine with paroxetine could not confirm any advantage of given intravenously in a dose of 5 to 20 micrograms by 3 O additive therapy. slow intravenous injection, repeated as necessary, usu- 1. Aronson R, et al. Triiodothyronine augmentation in the treat- HO I ally at intervals of 12 hours; the minimum interval be- ment of refractory depression: a meta-analysis. Arch Gen Psychi- OH atry 1996; 53: 842–8. tween doses is 4 hours. An alternative regimen advo- 2. Altshuler LL, et al. Does thyroid supplementation accelerate tri- NH2 cates an initial dose of 50 micrograms intravenously cyclic antidepressant response? A review and meta-analysis of I O the literature. Am J Psychiatry 2001; 158: 1617–22. followed by further injections of 25 micrograms every 3. Appelhof BC, et al. Triiodothyronine addition to paroxetine in I 8 hours until improvement occurs; the dosage may the treatment of major depressive disorder. J Clin Endocrinol then be reduced to 25 micrograms intravenously twice Metab 2004; 89: 6271–6. (liothyronine) daily. Obesity. Thyroid drugs have been tried in the treatment of obes- Liothyronine has also been given in the diagnosis of ity (p.2149) in euthyroid patients, but they produce only tempo- NOTE. The abbreviation T3 is often used for endogenous tri-io- hyperthyroidism in adults. Failure to suppress the up- rary weight loss, mainly of lean body-mass, and can produce se- dothyronine in medical and biochemical reports. Liotrix is USAN rious adverse effects, especially cardiac complications.1 for a mixture of liothyronine sodium with levothyroxine sodium.
    [Show full text]
  • CYTOMEL - Liothyronine Sodium Tablet Physicians Total Care, Inc
    CYTOMEL - liothyronine sodium tablet Physicians Total Care, Inc. ---------- Drugs with thyroid hormone activity, alone or together with other therapeutic agents, have been used for the treatment of obesity. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects. DESCRIPTION Thyroid hormone drugs are natural or synthetic preparations containing tetraiodothyronine (T4, levothyroxine) sodium or triiodothyronine (T3, liothyronine) sodium or both. T4 and T3 are produced in the human thyroid gland by the iodination and coupling of the amino acid tyrosine. T4 contains four iodine atoms and is formed by the coupling of two molecules of diiodotyrosine (DIT). T3 contains three atoms of iodine and is formed by the coupling of one molecule of DIT with one molecule of monoiodotyrosine (MIT). Both hormones are stored in the thyroid colloid as thyroglobulin. Thyroid hormone preparations belong to two categories: (1) natural hormonal preparations derived from animal thyroid, and (2) synthetic preparations. Natural preparations include desiccated thyroid and thyroglobulin. Desiccated thyroid is derived from domesticated animals that are used for food by man (either beef or hog thyroid), and thyroglobulin is derived from thyroid glands of the hog. The United States Pharmacopeia (USP) has standardized the total iodine content of natural preparations. Thyroid USP contains not less than (NLT) 0.17 percent and not more than (NMT) 0.23 percent iodine, and thyroglobulin contains not less than (NLT) 0.7 percent of organically bound iodine.
    [Show full text]
  • Potassium Perchlorate Hazard Summary
    Common Name: POTASSIUM PERCHLORATE CAS Number: 7778-74-7 RTK Substance number: 1577 DOT Number: UN 1489 Date: July 1988 Revision: May 2002 ------------------------------------------------------------------------- ------------------------------------------------------------------------- HAZARD SUMMARY WORKPLACE EXPOSURE LIMITS * Potassium Perchlorate can affect you when breathed in. No occupational exposure limits have been established for * Contact can irritate the skin and eyes. Potassium Perchlorate. This does not mean that this * Breathing Potassium Perchlorate can irritate the nose and substance is not harmful. Safe work practices should always throat. be followed. * High and repeated exposure may affect the thyroid, white blood cells and kidneys. WAYS OF REDUCING EXPOSURE * Where possible, enclose operations and use local exhaust IDENTIFICATION ventilation at the site of chemical release. If local exhaust Potassium Perchlorate is a colorless to white crystalline ventilation or enclosure is not used, respirators should be (sand-like) solid. It is used in explosives, flares, rocket worn. propellants, photography, as a medication, and as an agent in * Wear protective work clothing. automobile safety air bags. * Wash thoroughly immediately after exposure to Potassium Perchlorate and at the end of the workshift. REASON FOR CITATION * Post hazard and warning information in the work area. In * Potassium Perchlorate is on the Hazardous Substance addition, as part of an ongoing education and training List because it is cited by DOT. effort, communicate all information on the health and * Definitions are provided on page 5. safety hazards of Potassium Perchlorate to potentially exposed workers. HOW TO DETERMINE IF YOU ARE BEING EXPOSED The New Jersey Right to Know Act requires most employers to label chemicals in the workplace and requires public employers to provide their employees with information and training concerning chemical hazards and controls.
    [Show full text]
  • Hyper and Hypothyroidism
    Editing File Mnemonic File Endocrine Block Pharmacology team 438 Hyper and Hypothyroidism Objectives: By the end of the lecture , you should know: ● Describe different classes of drugs used in hyperthyroidism and hypothyroidism and their mechanism of action ● Understand their pharmacological effects, clinical uses and adverse effects ● Recognize treatment of special cases such as hyperthyroidism during pregnancy, Graves’ disease and Thyroid Storm and special cases of hypothyroidism such as myxedema coma Color index: Black : Main content Purple: Females’ slides only Red : Important Grey: Extra info or explanation Blue: Males’ slides only Green : Dr. notes Hyperthyroidism Thyroid Function ● Normal amount of thyroid hormones are essential for normal growth and development by maintaining the level of energy metabolism in the tissue. ● Either too little or too much thyroid hormones will bring disorders to the body. Important Functions CVS: increase Growth & Thermoregulation Helps maintain heart rate & development, increase basal metabolic cardiac output especially in the metabolic rate energy balance which increase embryo & brain (BMR) oxygen demand Iodine Importance ● Thyroid hormones are unique biological molecules in that they incorporate iodine1 in their structure ● Adequate iodine intake (diet, water) is required for normal thyroid hormone production ● Major sources of iodine are: iodized salt, iodated bread, dairy products, shellfish ● Minimum requirement: 75 micrograms/day Iodine Metabolism 1 2 3 Iodide taken up by the Dietary iodine
    [Show full text]